25-hydroxyvitamin D concentration is inversely associated with serum MMP-9 in a cross-sectional study of African American ESRD patients

BMC Nephrology

Volumn 12, Issue 1, 2011, Pages

  Wasse, Haimanot ^a,b   Cardarelli, Francesca ^c   De Staercke, Christine ^d   Hooper, Craig ^d   Veledar, Emir ^c   Guessous, Idris ^b,e,f  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM; GELATINASE A; GELATINASE B; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHORUS; TRIACYLGLYCEROL; 25-HYDROXYVITAMIN D; DRUG DERIVATIVE; VITAMIN D;

ADULT; AFRICAN AMERICAN; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; BLOOD; CHRONIC KIDNEY FAILURE; ETHNOLOGY; INFLAMMATION; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RISK FACTOR; STATISTICAL MODEL; UNITED STATES; VASCULAR DISEASE;

ADULT; AFRICAN AMERICANS; AGED; BIOLOGICAL MARKERS; CALCIUM; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-10; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PHOSPHORUS; RENAL DIALYSIS; RISK FACTORS; UNITED STATES; VASCULAR DISEASES; VITAMIN D;

EID: 79956227341     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-12-24     Document Type: Article

References (31)

1. Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis. A Segarra P Chacon C Martinez-Eyarre X Argelaguer J Vila P Ruiz J Fort J Bartolome J Camps E Moliner,, et al. J Am Soc Nephrol 2001 12 1255 1263 11373350 (Pubitemid 32472640)
2. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. JY Yeun RA Levine V Mantadilok GA Kaysen, Am J Kidney Dis 2000 35 469 476 10.1016/S0272-6386(00)70200-9 10692273 (Pubitemid 30124077)
3. Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. C Zoccali FA Benedetto F Mallamaci G Tripepi I Fermo A Foca R Paroni LS Malatino, J Hypertens 2000 18 1207 1213 10.1097/00004872-200018090- 00006 10994751
4. Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. CA Peterson ME Heffernan, J Inflamm (Lond) 2008 5 10 10.1186/1476-9255-5-10
5. Bone turnover in prolonged critical illness: effect of vitamin D. G Van den Berghe D Van Roosbroeck P Vanhove PJ Wouters L De Pourcq R Bouillon, J Clin Endocrinol Metab 2003 88 4623 4632 10.1210/jc.2003-030358 14557432 (Pubitemid 37357503)
6. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. SS Schleithoff A Zittermann G Tenderich HK Berthold P Stehle R Koerfer, Am J Clin Nutr 2006 83 754 759 16600924 (Pubitemid 44713136)
7. Role of matrix metalloproteinase inhibitors in preventing abdominal aortic aneurysm. F Aziz H Kuivaniemi, Ann Vasc Surg 2007 21 392 401 10.1016/j.avsg.2006.11.001 17484978 (Pubitemid 46678660)
8. Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease. RS Friese F Rao S Khandrika B Thomas MG Ziegler GW Schmid-Schonbein DT O'Connor, Clin Exp Hypertens 2009 31 521 533 10.3109/10641960802668730 19886850
9. Upregulation of MMP-9 production by TNFalpha in keratinocytes and its attenuation by vitamin D. K Bahar-Shany A Ravid R Koren, J Cell Physiol 2010 222 729 737 20020446
10. Effect of 1, 25 dihydroxyvitamin D(3) on matrix metalloproteinases MMP-7, MMP-9 and the inhibitor TIMP-1 in pulmonary tuberculosis. SP Anand P Selvaraj, Clin Immunol 2009 133 126 131 10.1016/j.clim.2009.06.009 19615945
11. 1alpha,25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection. A Coussens PM Timms BJ Boucher TR Venton AT Ashcroft KH Skolimowska SM Newton KA Wilkinson RN Davidson CJ Griffiths,, et al. Immunology 2009 127 539 548 10.1111/j.1365-2567.2008.03024.x 19178594
12. Expression of vitamin D receptors and matrix metalloproteinases in osteoarthritic cartilage and human articular chondrocytes in vitro. LC Tetlow DE Woolley, Osteoarthritis Cartilage 2001 9 423 431 10.1053/joca.2000.0408 11467890 (Pubitemid 32737182)
13. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. A Rahman S Hershey S Ahmed K Nibbelink RU Simpson, J Steroid Biochem Mol Biol 2007 103 416 419 10.1016/j.jsbmb.2006.12.081 17275288 (Pubitemid 46415673)
14. 25-hydroxyvitamin D levels and the risk of mortality in the general population. ML Melamed ED Michos W Post B Astor, Arch Intern Med 2008 168 1629 1637 10.1001/archinte.168.15.1629 18695076
15. Vitamin D levels and early mortality among incident hemodialysis patients. M Wolf A Shah O Gutierrez E Ankers M Monroy H Tamez D Steele Y Chang CA Camargo Jr M Tonelli R Thadhani, Kidney Int 2007 72 1004 1013 10.1038/sj.ki.5002451 17687259 (Pubitemid 47530570)
16. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. JP Forman E Giovannucci MD Holmes HA Bischoff-Ferrari SS Tworoger WC Willett GC Curhan, Hypertension 2007 49 1063 1069 10.1161/HYPERTENSIONAHA.107.087288 17372031 (Pubitemid 351664326)
17. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. E Giovannucci Y Liu BW Hollis EB Rimm, Arch Intern Med 2008 168 1174 1180 10.1001/archinte.168.11.1174 18541825 (Pubitemid 351831400)
18. 25-Hydroxyvitamin D Levels Inversely Associate with Risk for Developing Coronary Artery Calcification. IH de Boer B Kestenbaum AB Shoben ED Michos MJ Sarnak DS Siscovick, J Am Soc Nephrol 2009
19. Venous stenosis in a pig arteriovenous fistula model - anatomy, mechanisms and cellular phenotypes. Y Wang M Krishnamoorthy R Banerjee J Zhang S Rudich C Holland L Arend P Roy-Chaudhury, Nephrol Dial Transplant 2008 23 525 533 18037619 (Pubitemid 351767606)
20. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? PM Timms N Mannan GA Hitman K Noonan PG Mills D Syndercombe-Court E Aganna CP Price BJ Boucher, QJM 2002 95 787 796 10.1093/qjmed/95.12.787 12454321 (Pubitemid 36032948)
21. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. FJ Barrat DJ Cua A Boonstra DF Richards C Crain HF Savelkoul R de Waal-Malefyt RL Coffman CM Hawrylowicz A O'Garra, J Exp Med 2002 195 603 616 10.1084/jem.20011629 11877483 (Pubitemid 34461505)
22. Intervention in autoimmunity: the potential of vitamin D receptor agonists. L Adorini, Cell Immunol 2005 233 115 124 10.1016/j.cellimm.2005.04.013 15936743 (Pubitemid 41074064)
23. 1,25-dihydroxyvitamin D(3) promotes IL-10 production in human B cells. G Heine U Niesner HD Chang A Steinmeyer U Zugel T Zuberbier A Radbruch M Worm, Eur J Immunol 2008 38 2210 2218 10.1002/eji.200838216 18651709
24. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. P Alborzi NA Patel C Peterson JE Bills DM Bekele Z Bunaye RP Light R Agarwal, Hypertension 2008 52 249 255 10.1161/HYPERTENSIONAHA.108.113159 18606901
25. Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels. GA Preston CV Barrett DA Alcorta SL Hogan L Dinwiddie JC Jennette RJ Falk, Nephron 2002 92 817 823 10.1159/000065464 12399626 (Pubitemid 36151362)
26. Serum levels of vitamin D and haemostatic factors in healthy subjects: the Tromso study. R Jorde E Haug Y Figenschau JB Hansen, Acta Haematol 2007 117 91 97 10.1159/000097383 17135721
27. Matrix metalloproteinases as modulators of inflammation and innate immunity. WC Parks CL Wilson YS Lopez-Boado, Nat Rev Immunol 2004 4 617 629 10.1038/nri1418 15286728 (Pubitemid 39025047)
28. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. S Lacraz LP Nicod R Chicheportiche HG Welgus JM Dayer, J Clin Invest 1995 96 2304 2310 10.1172/JCI118286 7593617
29. Elevated plasma MMP1 and MMP9 are associated with abdominal aortic aneurysm rupture. WR Wilson M Anderton EC Choke J Dawson IM Loftus MM Thompson, Eur J Vasc Endovasc Surg 2008 35 580 584 10.1016/j.ejvs.2007.12.004 18226564 (Pubitemid 351469942)
30. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. MA Hlatky E Ashley T Quertermous DB Boothroyd P Ridker A Southwick RM Myers C Iribarren SP Fortmann AS Go, Am Heart J 2007 154 1043 1051 10.1016/j.ahj.2007.06.042 18035073 (Pubitemid 350116029)
31. The kind of vascular access influences the baseline inflammatory status and epoetin response in chronic hemodialysis patients. E Movilli G Brunori C Camerini V Vizzardi P Gaggia S Cassamali F Scolari G Parrinello GC Cancarini, Blood Purif 2006 24 387 393 10.1159/000093681 16755161 (Pubitemid 44215184)